Grifols (GRFS) Cash & Equivalents Growth (1y) (2010 - 2025)
Grifols (GRFS) Cash & Equivalents Growth (1y) (2010 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 9.93% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 1.58% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -14.46% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 14.42% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -30.58% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 74.25% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -38.20% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -40.42% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -13.23% |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - | -8.30% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -99.11% |
| Dec 31, 2024 | 83.05% |
| Dec 31, 2023 | 1.62% |
| Dec 31, 2022 | -81.70% |
| Dec 31, 2021 | 342.97% |
| Dec 31, 2020 | -15.85% |
| Sep 30, 2020 | 36.92% |
| Mar 31, 2020 | 7.39% |
| Dec 31, 2019 | -30.40% |
| Sep 30, 2019 | 30.21% |
| Mar 31, 2019 | -36.97% |
| Dec 31, 2018 | 13.04% |
| Jun 30, 2018 | -3.28% |
| Dec 31, 2017 | 8.02% |
| Jun 30, 2017 | -9.53% |
| Dec 31, 2016 | -22.83% |
| Sep 30, 2016 | 1.32% |
| Jun 30, 2016 | -99.90% |
| Mar 31, 2016 | 23.30% |
| Dec 31, 2015 | -7.15% |